+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Digoxin-Like Immunoreactive Substance in Renal Failure: A Reappraisal



      S. Karger AG

      Renal failure, Digoxin, Digoxin-like immunoreactivity, Immunoassay

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A digoxin-like immunoreactive substance (DLIS) has been described in the sera of patients with renal impairment. To further investigate this problem, we measured digoxin in 50 patients with elevated serum creatinine using 4 commercial digoxin immunoassay kits (3 radioimunoassay methods and 1 fluorescence polarization immunoassay technique). Ten of the patients were receiving digoxin therapeutically, while the remainder were not receiving the drug. Two of the radioimmunoassay kits detected low amounts of DLIS in 23% of the subjects not receiving digoxin, the highest level being 0.5 nmol/l. No DLIS was detected by the other radioimmunoassay kit or by the fluorescence polarization technique. The majority of renal patients receiving digoxin had similar results by all 4 methods, although 2 patients differed by 0.6 nmol/l as measured by 2 of the radioimmunoassay kits. We conclude that the extent of interference by DLIS in digoxin immunoassays in patients with renal impairment is not as great as has been previously reported.

          Related collections

          Author and article information

          S. Karger AG
          05 December 2008
          : 44
          : 2
          : 108-110
          Department of Laboratory Medicine, Ottawa General Hospital, and Department of Pathology, University of Ottawa, Canada
          183976 Nephron 1986;44:108–110
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Original Paper

          Cardiovascular Medicine, Nephrology

          Renal failure, Digoxin-like immunoreactivity, Digoxin, Immunoassay


          Comment on this article